Delivering Safe, Effective, Affordable, Personalized Therapies for Cancer Patients Faster

With industry eagerly anticipating readouts from Merck and Moderna’s Phase 3 trial of adjuvant V940 in combination with Keytruda, BioNTech, and Genentech’s global trials for BNT116 for non-small cell lung cancer, we are advancing ever closer to a commercially approved personalized cancer vaccine. Beyond mRNA, though, the field is expanding, as novel DNA, peptide, viral, and cellular therapies accelerate towards the clinic and showcase improvements in efficacy and safety.

The 2nd Annual Personalized Cancer Vaccine Summit returned to Boston as the only strategic forum dedicated to platforming the full spectrum of individualized cancer vaccines. We armed this community with the means to accelerate the development of their personalized immunotherapies for cancer patients in need.

With granular insights from early discovery and preclinical efforts through to the optimization of clinical and manufacturing strategies. This meeting was your one-stop shop to benchmark against competitors, challenges in efficacy, cost-effectiveness, and safety, and hear the latest clinical data poised to shape the field. Plus, in-depth discussions and data-driven case studies showcase the breadth of modalities in development, enabling you to gain cross-modality learnings to improve your vaccine’s efficacy at the tumor level and ensure you select the right neoantigen type to set your vaccine up for success.

We were joined by 80+ CXOs, VPs, and Directors of Oncology, Immunotherapy, and Vaccine R&D from the field’s leading biopharma organizations to gain the insights and partners you require to translate your personalized vaccines and individualized immunotherapies into robust clinical candidates and commercially viable products for multiple tumor types.